Form 4: Aquestive Therapeutics Executive Sells Shares Under 10b5-1 Trading Plan

Alexander Mark Schobel, Chief Innovation/Tech Officer of Aquestive Therapeutics, sold 25,000 shares of common stock on March 8, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Alexander Mark Schobel, Chief Innovation/Tech Officer of Aquestive Therapeutics, sold 25,000 shares of common stock on March 8, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted on December 16, 2023.
• The weighted average sales price was $5.1874 per share, with prices ranging from $5.00 to $5.60.
• Additionally, 5,895 shares were withheld by the issuer on March 9, 2024, to cover the reporting person's tax obligations related to vesting Restricted Stock Units (RSUs).
• Following these transactions, Schobel directly owns 1,034,476 shares of Aquestive Therapeutics.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to stock sales by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about transactions.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity. It's common for executives to use 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholders if it creates downward pressure on the stock price, although the impact is likely to be minimal given the relatively small volume of shares sold under the 10b5-1 plan.

Key Dates